INT107755

Context Info Confidence 0.52 First Reported 2003 Last Reported 2003 Negated 0 Speculated 0 Reported most in Abstract Documents 1 Total Number 3 Disease Relevance 0.71 Pain Relevance 0.45

cytosol (HSD17B1) small molecule metabolic process (HSD17B1) oxidoreductase activity (HSD17B1) cytoplasm (HSD17B1)

HSD17B1 (Homo sapiens)

Pain Link Frequency Relevance Heat cytokine 9 99.98 agonist 3 99.74 Clonidine 3 97.56

Disease Link Frequency Relevance Heat Obesity 12 98.60

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In a previous study, we noted that patients with hypothalamic obesity had an increased ratio of cortisol/cortisone metabolites, suggesting enhanced 11 beta-HSD-1 activity.

Positive_regulation (enhanced) of beta-HSD-1 associated with obesity

1) Confidence 0.52 Published 2003 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12519881 Disease Relevance 0.25 Pain Relevance 0.04

TNF alpha up-regulated 11 beta-HSD-1 activity maximally at 0.6 x 10(-9) M (140 +/- 20%; P < 0.001); the same cytokine increased 11 beta-HSD-1 mRNA levels to 3-fold of control (P < 0.05) and increased medium glycerol levels to 165 +/- 14% of control (P < 0.01).

Positive_regulation (increased) of beta-HSD-1 associated with cytokine

2) Confidence 0.52 Published 2003 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12519881 Disease Relevance 0.25 Pain Relevance 0.18

Of the adrenergic agonists, salbutamol up-regulated 11 beta-HSD-1 activity maximally at 10(-7) M (162 +/- 46%; P < 0.02), and clonidine down-regulated it at 10(-7) M (82 +/- 15%; P < 0.005).

Positive_regulation (up-regulated) of beta-HSD-1 associated with agonist and clonidine

3) Confidence 0.35 Published 2003 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12519881 Disease Relevance 0.21 Pain Relevance 0.22

General Comments

This test has worked.